Under-reporting of drug use among individuals with schizophrenia: Prevalence and predictors

Psychological Medicine

Volumn 44, Issue 1, 2014, Pages 61-69

  Bahorik, A L ^a,b   Newhill, C E ^a   Queen, C C ^a   Eack, S M ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Neurocognition; radioimmunoassay of hair; schizophrenia; self report drug use assessment; urine drug screen

Indexed keywords

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; CANNABIS ADDICTION; CAUCASIAN; CHEMISTRY; COCAINE DEPENDENCE; DRUG ABUSE; FEMALE; HAIR; HUMAN; INTERPERSONAL COMMUNICATION; MALE; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SELF REPORT; STATISTICAL MODEL; STATISTICS; SUBSTANCE ABUSE; URINE;

ADULT; AFRICAN AMERICANS; AGE FACTORS; AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; DISCLOSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HAIR; HUMANS; LOGISTIC MODELS; MALE; MARIJUANA ABUSE; MIDDLE AGED; RADIOIMMUNOASSAY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SELF REPORT; SUBSTANCE ABUSE DETECTION;

EID: 84889811147     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291713000548     Document Type: Article

References (51)

1. Baumgartner W, Hill V, Blahd W (1989). Hair analysis for drug of abuse. Journal of Forensic Sciences 34, 1433-1453.
2. Bell M, Milstein R, Beam-Goulet J, Lysaker P, Cicchetti D (1992). The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale: reliability, comparability, and predictive validity. Journal of Nervous and Mental Disease 180, 723-728. (Pubitemid 23009554)
3. Carey K, Correia C (1998). Severe mental illness and addictions: Assessment considerations. Addictive Behaviors 23, 735-748. (Pubitemid 28443189)
4. Degenhardt L, Hall W (2001). The association between psychosis and problematic drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. Psychological Medicine 31, 659-668. (Pubitemid 32421967)
5. Dixon L (1999). Dual diagnosis of substance abuse in schizophrenia: prevalence and impact on outcomes. Schizophrenia Research 35, S93-S100. (Pubitemid 29133030)
6. Dixon L, Haas G, Dulit R, Weiden P, Sweeney J, Hien D (1989). Substance abuse in schizophrenia: preferences, predictors, and psychopathology. Schizophrenia Research 2, 6.
7. Dixon L, Haas G, Weiden P, Sweeney J, Frances A (1990). Acute effects of drugs abuse in schizophrenic patients: clinical observations and patients' self-report. Schizophrenia Bulletin 16, 69-79. (Pubitemid 20110376)
8. Dixon L, Haas G, Weiden P, Sweeney J, Frances A (1991). Drug abuse in schizophrenic patients: clinical correlates and reasons for use. American Journal of Psychiatry 148, 224-230.
9. Drake R, Mueser K (2001). Managing comorbid schizophrenia and substance abuse. Current Psychiatry Reports 3, 418-422.
10. Eack S, Greenwald D, Hogarty S, Cooley S, DiBarry A, Montrose D, Keshavan M (2009). Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatric Services 60, 1468-1476.
11. First M, Spitzer R, Gibbon M, Williams J (1996). Structured Clinical Interview for Axes I and II DSM-IV Disorders-Patient Edition (SCID-I/P). Biometrics Research Department, New York State Psychiatric Institute: New York.
12. Fowler I, Carr V, Carter N, Lewin T (1998). Patterns of current and lifetime substance use in schizophrenia. Schizophrenia Bulletin 24, 443-455. (Pubitemid 28378229)
13. Galletly C, Field C, Prior M (1993). Urine drug screening of patients admitted to a state psychiatric hospital. Hospital Community Psychiatry 44, 587-589. (Pubitemid 23185873)
14. Green M, Kern R, Heaton R (2004b). Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophrenia Research 72, 41-51. (Pubitemid 39452904)
15. Green M, Nuechterlein J, Barch D, Cohen J, Essock S, Fenton W, Frese F, Goldberg T, Heaton R, Keefe R, Kern R, Kraemer H, Stover E, Weinberger D, Zalcman S, Marder S (2004b). Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS Conference to Select Cognitive Domains and Test Criteria. Biological Psychiatry 56, 301-307. (Pubitemid 39164514)
16. Gregg L, Barrowclough C, Haddock G (2006). Increased substance use in psychosis. Clinical Psychology Review 27, 494-510.
17. Hjorthøj CR, Hjorthøj AR, Nordentoft M (2012). Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances-systematic review and meta-analysis. Addictive Behaviors 37, 225-233.
18. Kavanagh DJ, Waghorn G, Jenner L, Chant DC, Carr V, Evans M (2004). Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophrenia Research 66, 115-124. (Pubitemid 38041109)
19. Kay S, Fiszbein A, Opler L (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-227.
20. Keefe R, Mohs R, Bilder R, Harvey P, Green M, Meltzer H, Gold J, Sano M (2003). Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. Schizophrenia Bulletin 29, 45-55. (Pubitemid 36871056)
21. Kessler RC (2004). The epidemiology of dual diagnosis. Biological Psychiatry 54, 730-737. (Pubitemid 39539830)
22. Kline J, Stphen KC, Schittini M, Levin B, Susser M (1997). Cocaine use during pregnancy: sensitive detection by hair assay. American Journal of Public Health 87, 352-358. (Pubitemid 27157445)
23. Ledgerwood DM, Goldberger BA, Risk NK, Lewis NK, Rumi KP (2008). Comparison between self-report and hair analysis of illicit drug use in a community sample of middle-aged men. Addictive Behaviors 33, 1131-1139.
24. Lehman A, Steinwachs D (1998). Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin 24, 1-10. (Pubitemid 28128486)
25. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223. (Pubitemid 41345943)
26. Magura S, Freeman R, Siddiqi Q, Lipton D (1992). The validity of hair analysis for detecting cocaine and heroin use among addicts. International Journal of the Addictions 27, 51-69.
27. McEvoy JP, Apperson LJ, Appelbaum PS, Ortlip P, Brecosky J, Hammill K, Geller JL, Roth L (1989). Insight in schizophrenia. Its relationship to acute psychopathology. Journal of Nervous and Mental Disease 177, 43-47. (Pubitemid 19043858)
28. Mieczkowski T, Barzelay D, Gropper B (1991). Concordance of three measures of cocaine use in an arrestee population: hair, urine, and self-report. Journal of Psychoactive Drugs 23, 241-249.
29. Mieczkowski T, Newel R (1993). Comparing hair and urine assays for cocaine and marijuana. Federal Probation 57, 59-67.
30. Møller T, Linaker O (2010). Using brief self-reports and clinician scales to screen for substance use disorders in psychotic patients. Nordic Journal of Psychiatry 64, 130-135.
31. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, Essock S, Fenton WS, Frese 3rd FJ, Gold JM, Goldberg T, Heaton RK, Keefe RS, Kraemer H, Mesholam-Gately R, Seidman LJ, Stover E, Weinberger DR, Young AS, Zalcman S, Marder SR (2008). The MATRICS Consensus Cognitive Battery, Part 1: Test selection, reliability and validity. American Journal of Psychiatry 165, 203-213. (Pubitemid 351704520)
32. Pragst F, Balikova M (2006). State of the art in hair analysis for detection of drug and alcohol abuse. Clinica Chimica Acta 370, 17-49. (Pubitemid 44137285)
33. Rabin RA, Zakzanis KK, George TP (2011). The effects of cannabis use on neurocognition in schizophrenia: A meta-analysis. Schizophrenia Research 128, 111-116.
34. Reiger D, Farmer M, Rae D, Locke B, Keith S, Judd L, Goodwin F (1990). Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemologic Catchment Area (ECA) Study. Journal of the American Medical Association 264, 2511-2518.
35. Reimherr F, Swartz M, Olsen J (2010). Substance use in persons with schizophrenia: incidence, baseline correlates, and effects on outcome. In Antipsychotic Trials in Schizophrenia (ed. S. T. Stroup and J. A. Liberman), pp. 189-206. Cambridge University Press: New York
36. Schiffer B, Bernhard B, Scherbaum N, Forsting M, Wiltfang J, Leygraf N, Gizewski E (2010). Impulsivityrelated brain volume deficits in schizophrenia-addiction comorbidity. Brain 133, 3093-3103.
37. Shaner A, Khalsa M, Roberts L, Wilkins D, Hsieh S (1993). Unrecognized cocaine use among schizophrenic patients. American Journal of Psychiatry 150, 758-762. (Pubitemid 23137682)
38. Stone AM, Greenstein RA, Gamble G, McLellan AT (1993). Cocaine use by schizophrenic outpatients who receive depot neuroleptic medication. Hospital Community Psychiatry 44, 176-177. (Pubitemid 23075201)
39. Stroup T, McEvoy J, Swartz M, Byerly M, Blick I, Canive J, McGee M, Simpson G, Stevens M, Liberman J (2003). The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophrenia Bulletin 29, 15-31. (Pubitemid 36871054)
40. Swartz M, Swanson J, Hannon M (2003). Detection of illicit substance use among persons with schizophrenia. Psychiatric Services 54, 891-895. (Pubitemid 36629102)
41. Swartz M, Wagner H, Swanson J, Stroup S, McEvoy J, Canive J, Miller D, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck R, Liberman J (2006a). Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 194, 164-172.
42. Swartz M, Wagner H, Swanson J, Stroup S, McEvoy J, McGee M, Miller D, Reimherr F, Khan A, Canive J, Liberman J (2006b). Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 57, 1110-1116. (Pubitemid 44204903)
43. Van Dorn R, Desmarais S, Young S, Sellers B, Swartz M (2012). Assessing illicit drug use among adults with schizophrenia. Psychiatry Research 200, 228-236.
44. Verstraete A (2004). Detection times of drugs of abuse in blood urine, an oral fluid. Therapeutic Drug Monitoring 26, 200-205. (Pubitemid 38501218)
45. Vincenti A, Ventrigilo A, Baldessarini R, Talamo A, Fitzmaurico G, Centorrino F (2010). Characteristics and clinical changes during hospitalization in bipolar and psychiatric disorder patients with and without substance use disorders. Pharmacopsychiatry 43, 225-232.
46. Volkow N (2009). Substance use disorders in schizophrenia-clinical implications of comorbidity. Schizophrenia Bulletin 35, 469-472.
47. Weiss R, Najavits L, Greenfield S, Soto J, Shaw S, Wyner D (1998). Validity of substance use self-reports in dually diagnosed outpatients. American Journal of Psychiatry 155, 127-128. (Pubitemid 28037561)
48. Welch M, Sniegoski L, Allgood C, Habram M (1993). Hair analysis for drugs of abuse: evaluation of analytical methods. Environmental issues and development of reference materials. Journal of Analytical Toxicology 17, 389-398. (Pubitemid 23344821)
49. Woods S (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 64, 663-667. (Pubitemid 36750143)
50. Yücel M, Bora E, Lubman D, Solowij N, Brewer W, Cotton S, Conus P, Takagi M, Fornito A, Wood S, McGorry P, Pantelis C (2010). The impact of cannabis use on cognitive functioning in patients with schizophrenia: A meta-analysis of existing findings and new data in a first-episode sample. Schizophrenia Bulletin 38, 316-330.
51. Zedonis D, Smelson D, Rosenthal R, Batki S, Green A, Henry R, Montoya I, Parks J, Weiss R (2005). Improving the care of individuals with schizophrenia and substance use disorders. Consensus recommendations. Journal of Psychiatric Practice 1, 315-339. (Pubitemid 41540226)